Intervention Review

You have free access to this content

Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults

  1. Mattias Linde1,*,
  2. Wim M Mulleners2,
  3. Edward P Chronicle3,
  4. Douglas C McCrory4,5

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 24 JUN 2013

Assessed as up-to-date: 15 JAN 2013

DOI: 10.1002/14651858.CD010609


How to Cite

Linde M, Mulleners WM, Chronicle EP, McCrory DC. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010609. DOI: 10.1002/14651858.CD010609.

Author Information

  1. 1

    Norwegian University of Science and Technology, Department of Neuroscience, Trondheim, Norway

  2. 2

    Canisius Wilhelmina Ziekenhuis, Department of Neurology, Nijmegen, Netherlands

  3. 3

    University of Hawaii at Manoa, (Deceased) Department of Psychology, Manoa, USA

  4. 4

    Duke University Medical Center, Department of Medicine, Durham, NC, USA

  5. 5

    Durham Veterans Affairs Medical Center, Center for Health Services Research in Primary Care, Durham, NC, USA

*Mattias Linde, Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway. mattias.linde@ntnu.no.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JUN 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Gabapentin versus placebo, Outcome 1 Headache frequency (change from baseline to post-treatment, or post-treatment alone).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Gabapentin versus placebo, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Gabapentin versus placebo, Outcome 3 Any adverse event.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Gabapentin versus placebo, Outcome 4 Asthenia/fatigue.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Gabapentin versus placebo, Outcome 5 Dizziness.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Gabapentin versus placebo, Outcome 6 Flu syndrome.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Gabapentin versus placebo, Outcome 7 Somnolence.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Gabapentin versus placebo, Outcome 8 Abnormal thinking.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Gabapentin enacarbil (GEn) versus placebo, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Gabapentin dose comparisons, Outcome 1 Headache frequency (post-treatment).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Gabapentin dose comparisons, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency).
[Analysis 4.1]
Analysis 4.1. Comparison 4 Gabapentin enacarbil (GEn) dose comparisons, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency).